Novo Nordisk to license obesity drug from Lexicon in up to $1 billion deal
Lexicon Pharmaceuticals said on Friday that Danish drugmaker Novo Nordisk has entered into a licensing deal with the company ...
Novo Nordisk Stock (NVO) Sees Its Largest Monthly Drop Since 2002
Novo Nordisk’s (NVO) stock has dropped by 25% in March (on the Copenhagen exchange) to put it on track for its biggest ...
DPA International on MSN6d
German software giant SAP becomes Europe's most valuable company
German software giant SAP has become the most valuable European company, replacing Danish pharmaceutical major Novo Nordisk.
Novo Nordisk defends disappointing next-gen obesity drug: ‘It will be an important product'
Novo Nordisk has defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, insisting it will be an “important” weight loss treatment.
Novo Nordisk's next-gen obesity drug CagriSema had investors excited. Now they're not so sure
Novo Nordisk’s hopes of heralding a new era of obesity treatment with its next-generation CagriSema drug may be in doubt ...
Reuters3d
Novo Nordisk to license obesity drug from Lexicon in up to $1 billion deal
March 28 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab is ... after its diabetes drug faced multiple setbacks. The company also said it would reduce its workforce by about 60%, after the ...